Cure My Disease

Don't miss your cure!

 Log in / Sign up

Paxlovid tested as a shield against long COVID in 2,000-Person trial

NCT ID NCT05852873

Ongoing Prevention Sponsor: Haukeland University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether taking Paxlovid (nirmatrelvir/ritonavir) during acute COVID-19 can prevent long COVID. About 2,000 adults aged 18-64 with a recent positive test and symptoms will receive either Paxlovid or a placebo for 5 days. Researchers will track long COVID symptoms like fatigue, breathing problems, and brain fog at 3 months to see if the drug reduces their occurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Paxlovid (nirmatrelvir/ritonavir)
What this could lead to
If it works, this could show that taking Paxlovid early during a COVID-19 infection reduces the risk of developing long COVID.
What could go wrong
This is a single study in Norway, and results may not apply to everyone. Long COVID is complex, and a short treatment may not prevent all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19 post-COVID-19 disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 POST COVID-19 CONDITION, UNSPECIFIED SARS-COV2 INFECTION

Contacts and locations

Locations

  • Haukeland University Hospital

    Bergen, Vestland, 5021, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.